Prior research has demonstrated that pyruvate kinase M2 (PKM2), the final rate-limiting enzyme of glycolysis, is predominantly expressed in various cancers, thus providing selective growth advantages over its counterpart, PKM1 [9, 10]. The gene discussed is PKM; the disease is cancer.